Welcome : Guest

CNS THERAPEUTICS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 162 companies including many key and niche players such as -

AbbVie Inc.
Alkermes Plc
Allergan, Plc
Amneal Pharmaceuticals, LLC
AstraZeneca Plc
BIAL Group

Click here to request a full list of companies covered in the report...

Code: MCP-1835
Price: $4950
Companies: 162
Pages: 611
Date: November 2017
Market Data Tables: 96
  Status: * New Report



TABLE OF CONTENTS


  CNS THERAPEUTICS (Complete Report) Pages : 611   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS
  Disorders.....II-1
2$200
   List of FDA Approved CNS Drugs: 2015 through 2017.....II-3
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS
  Market.....II-3
1$100
   Patent Expiries of Leading CNS Drugs: 2008-2022.....II-41$100
   Developed Markets to Maintain their Dominance.....II-5
Developing Market to Drive the Market Momentum.....II-5
2$200
   Anti-Epilepsy Market.....II-7
Global Market Overview.....II-7
Disease Overview.....II-7
1$100
   Table 1: Epilepsy Incidence by Type (2016): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy (includes corresponding Graph/Chart).....II-8

Table 2: Symptomatic Epilepsy Incidence by Type (2016): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy (includes corresponding Graph/Chart).....II-8
1$350
   Treatment.....II-91$100
   Anti-Epileptic Market (AEDs) by Drug Class: List of Drugs under Broad-Spectrum AEDs
  and Narrow-Spectrum AEDs.....II-10
Leading Anti-Epileptic Drugs.....II-10
1$100
   Leading Anti-Epileptic Drugs and Their Mechanism of Action.....II-11
Patent Expiries of Major Anti-Epilepsy Drugs.....II-11
High Unmet Needs Offer Scope for Market Growth.....II-11
1$100
   Select Currently Available Epilepsy Drugs.....II-121$100
   Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials.....II-13
Innovative Drugs Needed for Better Treatment Compliance.....II-13
1$100
   Abounding Potential for NCEs.....II-14
Developed Countries Account for a Major Share of Epilepsy Treatment.....II-14
1$100
   Developing Countries Struggle with Low Treatment Rates.....II-15
Refractory Childhood Epilepsy & Pregnancy Epilepsy – Major Concerns.....II-15
1$100
   Review of Anti-Epilepsy Drugs.....II-16
Vimpat®.....II-16
Keppra®.....II-16
Lamictal.....II-16
1$100
   Tegretol®.....II-17
Sabril®.....II-17
Perampanel.....II-17
Zonegran®.....II-17
Topamax®.....II-17
1$100
   Trileptal®.....II-18
Neurontin®.....II-18
Lyrica®.....II-18
Depakine®.....II-18
1$100
   CNS Pain Management.....II-19
Market Overview.....II-19
Treatment.....II-19
1$100
   Drugs Indicated for Pain Management.....II-201$100
   Select Phase III Completed Studies for Cancer Pain.....II-211$100
   Regional Overview.....II-22
Players.....II-22
Combination Therapies Gain Prominence.....II-22
Key Trends in Chronic Pain Management.....II-22
1$100
   Minimally Invasive Procedures Gain Popularity for Chronic Back Pain.....II-231$100
   Neuropathic Pain Management: Market with High Potential.....II-241$100
   Select Phase III Completed Studies for Neuropathic Pain.....II-251$100
   Migraine Market: A Core Vertical in CNS Pain Management.....II-26
Migraine Care: Select Patent Expiries (2013-2015).....II-26
New Pain Management Drugs.....II-26
1$100
   Recent Approvals in Pain Management: 2016-2017.....II-27
Select Pain Management Drugs.....II-27
Flupirtine.....II-27
Lyrica®.....II-27
Oxycodone.....II-27
Nucynta ER.....II-27
1$100
   Metabotropic Glutamate Receptors (mGluRs).....II-28
Anti-Alzheimer's.....II-28
Market Overview.....II-28
1$100
   Table 3: Alzheimer's Prevalence by Age Group (includes corresponding Graph/Chart).....II-29
Treatment for Alzheimer’s.....II-29
Select Leading Drugs for Alzheimer's Disease by Drug Category.....II-29
1$350
   Patent Expiries of Leading Alzheimer’s Drugs.....II-30
Drug Development Scenario for Alzheimer’s – Major Focus on Amyloid Targets.....II-30
Aducanumab – A Promising Drug for Alzheimer’s Disease.....II-30
2$200
   Phase III Pipeline Drugs for Alzheimer’s Disease.....II-321$100
   Prevention Gains Increasing Attention.....II-33
Novel Treatment for Alzheimer’s to Emerge.....II-33
Evolving Brain Imaging Technologies to Offer Early and Greater Accuracy.....II-33
1$100
   A Review of Select Anti-Alzheimer’s Drugs.....II-34
Aricept.....II-34
Exelon.....II-34
Reminyl.....II-34
Ebixa.....II-34
Namenda.....II-34
1$100
   Anti-Inflammatory Drug, Ponstel, Displays Potential to Treat Alzheimers in
  Mice.....II-35
Anti-Parkinson's.....II-35
Market Overview.....II-35
1$100
   Levodopa - The “Gold Standard” for Parkinson’s Treatment.....II-36
Xadago - New Approved Add-On Therapy for Parkinson’s Disease.....II-36
1$100
   NUPLAZID® - The First and the Only Approved Drug for Psychosis related to Parkinson’s
  disease.....II-37
MSDC-0160 – A Potential Drug Undergoing Animal Studies.....II-37
Select Anti-Parkinson’s Drugs.....II-37
Levodopa.....II-37
Dopamine Agonists.....II-37
1$100
   Mirapex.....II-38
Requip.....II-38
Anti-Depressants.....II-38
Market Overview.....II-38
1$100
   Anti-Depressant Treatment.....II-39
Low R&D Investments Restrict New Antidepressants Development.....II-39
1$100
   Select Antidepressants Drugs.....II-40
Zoloft (Sertraline).....II-40
Cymbalta®.....II-40
Prozac (Fluoxetine).....II-40
Effexor (Venlafaxine).....II-40
Paxil.....II-40
Wellbutrin (Bupropion).....II-40
1$100
   Anti-Psychotics.....II-41
Market Overview.....II-41
1$100
   Companies Focus on Next Generation Products to Deflect the Heat of
  Competition.....II-42
1$100
   Leading Atypical Antipsychotics for the Treatment of Schizophrenia.....II-431$100
   Promising Compounds in Clinical Development for the Treatment of Schizophrenia in
  Adults.....II-44
Select Anti-Psychotic Drugs.....II-44
1$100
   Zyprexa.....II-45
Seroquel.....II-45
Abilify.....II-45
1$100
   Clozaril.....II-46
Risperdal.....II-46
Risperdal® Consta®.....II-46
Geodon.....II-46
Invega Sustenna.....II-46
1$100
   Saphris.....II-47
Latuda.....II-47
Other CNS Disorders (ADHD, MS, and Insomnia).....II-47
1$100
   Attention Deficit Hyperactivity Disorder (ADHD).....II-48
Market Overview.....II-48
Approved Drugs for ADHD: 2017.....II-48
Pipeline Drugs for ADHD: As of March 2017.....II-48
Select ADHD Drugs.....II-48
Concerta.....II-48
1$100
   Adderall.....II-49
Multiple Sclerosis (MS).....II-49
Multiple Sclerosis Approved Therapies (Injectables).....II-49
1$100
   Multiple Sclerosis Approved Therapies (Oral).....II-50
Patent Expiration Date/Year of the Major MS Drugs.....II-50
Ocrevus – The First Approved Drug for Primary Progressive Multiple Sclerosis
  (PPMS).....II-50
Multiple Sclerosis: Pipeline Analysis.....II-50
Potential MS treatments, which are currently in Phase 3 Clinical Trials.....II-50
1$100
   Potential MS treatments, which are currently in Phase 2 Clinical Trials.....II-51
Potential Treatment for Primary Progressive MS, which are in Phase 3.....II-51
Potential Treatment for Primary Progressive MS, which are in Phase 2.....II-51
1$100
   Potential Treatment for Secondary Progressive MS, which are in Phase 3.....II-52
Potential Treatment for Secondary Progressive MS, Which are in Phase 2.....II-52
1$100
   Insomnia.....II-53
Overview.....II-53
Zolpidem.....II-53
Eszopiclone.....II-53
1$100
   Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand.....II-54 1$100
   Table 4: Aging Population by Age Group in More Developed Countries (1975-2050) (includes corresponding Graph/Chart).....II-551$350
   Table 5: Global Population Statistics for the 65+ Age Group (2016) (includes corresponding Graph/Chart).....II-561$350
   Table 6: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart).....II-571$350
   Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics
  Market.....II-58
Rising Healthcare Expenditure to Boost CNS Therapeutics Market.....II-58
1$100
   Table 7: Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart).....II-591$350
   Table 8: Healthcare Spending as a Percentage of GDP in Select Countries (2013) (includes corresponding Graph/Chart).....II-601$350
   Table 9: Global Middle Class Population (in Millions) by Geographic Region: 2010, 2020P & 2030P (includes corresponding Graph/Chart).....II-61

Table 10: Annual Disposable Incomes in US$ Thousand for Select Countries (2012) (includes corresponding Graph/Chart).....II-61
1$350
   Growing Penetration of Generic Drugs Emerges as a Key Trait.....II-62
Table 11: Global Spending on Generic Drugs Vis-à-vis Branded Drugs (2013 & 2018): Percentage Share Breakdown of Dollar Spending by Drug Category (includes corresponding Graph/Chart).....II-62
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs
  Market.....II-62
1$350
   Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A
  Case-in-Point.....II-63
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines.....II-63
1$100
   Awareness Campaigns Launched by Pharma Companies to Benefit the Market .....II-64
Music and Memory Programs Positively Impact Alzheimer’s Disease (AD) and Related
  Dementia (ADRD) Patients.....II-64
1$100
   New Method to Isolate Active Compounds Related to Alzheimers from Plant
  Medicines.....II-65
1$100
   Definition.....II-66
Central Nervous System.....II-66
Mortality Threat of CNS Disorders.....II-66
Science of NMDA Receptors and its Disease Significance.....II-66
1$100
   Major CNS Disorders:.....II-67
Alzheimer’s Disease.....II-67
1$100
   Alzheimer’s Effect on Brain.....II-68
Causes for Alzheimer’s.....II-68
Who Are at Risk?.....II-68
1$100
   Prevalence of Alzheimer’s Disease.....II-69
Diagnosis of Alzheimer’s.....II-69
Parkinson’s Disease.....II-69
1$100
   Prevalence.....II-70
Symptoms.....II-70
Causes.....II-70
1$100
   Diagnosis.....II-71
Epilepsy.....II-71
1$100
   Symptoms of Epilepsy.....II-72
Types of Epilepsy and Epileptic Seizures.....II-72
Preventive Measures.....II-72
1$100
   Treatment Options for Epilepsy Patients.....II-73
Treatment Options Available for Epilepsy Patients.....II-73
Epilepsy Drug Treatment Paradigm.....II-73
1$100
   Pain Management.....II-74
Debilitating Effects of Pain.....II-74
Types of Pain.....II-74
1$100
   Acute Pain.....II-75
Chronic Pain.....II-75
Migraine.....II-75
Neuropathic Pain.....II-75
1$100
   Nociceptive Pain.....II-76
Anti-Psychotics.....II-76
Bipolar Disorder.....II-76
Symptoms of Bipolar Disorder.....II-76
1$100
   Mood Episode – A Major Symptom.....II-77
Manic Episode Vs Depressive Episode.....II-77
1$100
   Causes of Bipolar Disorder.....II-78
Types of Bipolar Disorder.....II-78
Co-morbidities of Bipolar Disorder.....II-78
1$100
   Schizophrenia.....II-79
Prevalence by Gender.....II-79
Symptoms of Schizophrenia.....II-79
1$100
   Causes of Schizophrenia.....II-80
Therapies for Bipolar Disorder & Schizophrenia.....II-80
1$100
   Mood Stabilizing Agents.....II-81
Antidepressants.....II-81
1$100
   Antipsychotic Drugs.....II-82
Indications of Antipsychotics.....II-82
An Effective Adjunctive Therapy.....II-82
Off-label Uses.....II-82
1$100
   Efficacy – Marred by Lack of Evidence Base.....II-83
Types of Antipsychotics.....II-83
Difference between Typical and Atypical.....II-83
1$100
   Atypical Antipsychotics Up Against Typicals.....II-84
Side Effects of Antipsychotics.....II-84
1$100
   Symptoms of Antipsychotics Withdrawal.....II-851$100
   Controversies Surrounding Antipsychotics.....II-861$100
   Prohibited Practices.....II-87
Antipsychotics in Pregnant Women.....II-87
Depression.....II-87
1$100
   Prevalence of Depression.....II-88
Causes of Depression.....II-88
Types of Depressive Disorders.....II-88
Available Treatment.....II-88
1$100
   Tricyclic Antidepressants.....II-89
Monoamine Oxidase Inhibitors.....II-89
Lithium Salts.....II-89
Working of Antidepressants.....II-89
1$100
   Ranking of Antidepressants in Terms of Efficacy.....II-90
Types of Antidepressants.....II-90
NMDA Receptor Antagonists.....II-90
NMDA Receptor (NMDAR).....II-90
NMDA Receptor Agonists.....II-90
Acetylcholinesterase Inhibitors.....II-90
1$100
   Selective Serotonin Reuptake Inhibitors (SSRIs).....II-91
Workings of SSRIs.....II-91
Safety Levels of SSRI Drugs.....II-91
1$100
   Adverse Effects of SSRI.....II-92
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs).....II-92
Others Common CNS Disorders.....II-92
Attention Deficit Hyperactivity Disorder.....II-92
1$100
   Consequences of ADHD.....II-93
What Leads to ADHD?.....II-93
Treating ADHD.....II-93
1$100
   Multiple Sclerosis (MS).....II-94
Types of Multiple Sclerosis.....II-94
1$100
   Table 12: Clinical Subtypes of Multiple Sclerosis (MS) (includes corresponding Graph/Chart).....II-95
Prevalence of MS.....II-95
Causes of MS.....II-95
1$350
   Myths Surrounding Multiple Sclerosis.....II-96
Symptoms of MS.....II-96
Diagnosis of MS.....II-96
Treatment.....II-96
Insomnia.....II-96
1$100
   Prevalence of Insomnia.....II-97
Therapies for Insomnia.....II-97
1$100
   Scientists Discover New Epilepsy Drug in Fish Model.....II-98
A Smart Walking Stick for Parkinson’s Patients.....II-98
1$100
   New Technologies for Pain Management – A Threat to Opiod Therapeutics.....II-99
Radiofrequency Ablation Device.....II-99
Omron Healthcare’s HEAT Pain Pro™ TENS Device.....II-99
1$100
   BurstDR Stimulation from St Jude Medical, Inc.....II-100
Virtual Reality from DeepStream VR.....II-100
ActiPatch® from BioElectronics Corporation.....II-100
1$100
   Zydus Cadila's Anti-Depressant Drug Receives USFDA Approval.....II-101
Neurocrine’s 80 mg INGREZZA Capsules gets FDA Approval.....II-101
Roche’s OCREVUS gets Swiss Agency Approval.....II-101
Theranexus’S THN102 Drug Receives US Patent.....II-101
UCB’s AED VIMPAT gets EU Approval for Paediatric Use.....II-101
UCB’s AED BRIVIACT Receives Approval from FDA.....II-101
Dr Reddy’s Unveils Anti-Depressant & Muscle Relaxant Drugs.....II-101
1$100
   Sunovion Submits Drug Application to the FDA for Dasotraline.....II-102
Eisai Pharmaceuticals Unveils Anti-Epilepsy Drug Fycompa.....II-102
Eisai's Antiepileptic Drug gets Approval from FDA.....II-102
UCB’s AED gets EU CHMP Positive Opinion on License Extension.....II-102
Prexton Unveils Phase II Clinical Testing of its Investigational Drug Candidate in
  PD.....II-102
BIAL Introduces New Treatment Opicapone for Parkinson's Disease.....II-102
Sunovion’s Latuda Receives FDA Approval to Treat Bipolar Depression.....II-102
1$100
   Alkermes gets FDA Approval for Two-Month ARISTADA.....II-103
Lundbeck & Otsuka’s Brexpiprazole gets Approval from EMA.....II-103
Sumitomo Dainippon Pharma gets Import Drug License Approval from CFDA.....II-103
Minoryx’s MIN-102 gets Orphan Drug Designation by FDA.....II-103
Sunovion’s Latuda gets FDA Approval.....II-103
Tohoku University Introduces New Drug SAK3.....II-103
FYCOMPA® of Eisai Receives FDA Approval.....II-103
Proximagen Announces the Meeting of Primary Efficacy Endpoint for Midazolam Nasal
  Spray.....II-103
1$100
   GW Pharmaceuticals Announces Positive Results for Second Phase III Study of
  Epidiolex.....II-104
Daiichi Sankyo Reports Results of Two Pain Drugs.....II-104
Sumitomo Dainippon Pharma Declares Topline Results for Lurasidone from a Phase 3
  Study.....II-104
Ocrevus Receives FDA Approval.....II-104
FDA Scrutinizes Skin Reactions with Zecuity Sumatriptan Patch.....II-104
Zinbryta Receives FDA Approval for Treating Multiple Sclerosis.....II-104
1$100
   Tecfidera Emerges as a First-line Treatment for Relapsing-remitting Multiple Sclerosis
  (RRMS).....II-105
GlaxoSmithKline Announces the Discontinuation of Retigabine (Trobalt).....II-105
EISAI’S BACE Inhibitor E2609 gets Fast Track Designation from FDA.....II-105
Cleveland Clinic Lerner College of Medicine Unveils NTRX-07.....II-105
BIAL Introduces Opicapone.....II-105
iX Biopharma Unveils Next Drug BnoX.....II-105
Daiichi Sankyo & UCB Unveils Vimpat Tablets.....II-105
AstraZeneca & Lilly’s AZD3293 gets FDA Fast Track Designation.....II-105
1$100
   Eisai Introduces Fycompa (perampanel).....II-106
Novartis Drug Afinitor gets EU Approval.....II-106
TG Therapeutics to Start Phase 2 Clinical Study of TG-1101.....II-106
Acadia gets FDA Approval for the Nuplazid (pimavanserin) Drug.....II-106
AstraZeneca & Lilly’s AZD3293 Continues into Phase III of the Phase II/III Seamless
  Trial.....II-106
Zambon S.p.A and Newron Unveils Xadago (safinamide).....II-106
Lundbeck and Takeda gets CRL from FDA for Brintellix (vortioxetine) sNDA.....II-106
1$100
   Allergan Announces Availabilty of VRAYLAR in the US.....II-107
Otsuka’s gets Approval for ABILIFY.....II-107
Zambon and Newron Unveils Xadago (safinamide).....II-107
UCB gets EU Approval for New Epilepsy Drug BRIVIACT.....II-107
1$100
   Mylan Acquires Meda.....II-108
ProQR Splits Out Amylon Therapeutics for CNS Therapeutics.....II-108
Allergan Takes Over Lysosomal Therapeutics.....II-108
AstraZeneca Partners with Takeda.....II-108
Charles River Takes Over Brains On-Line.....II-108
Pairnomix Partners with StemoniX to Develop Epilepsy Model.....II-108
Accera Inks Partnership & Licensing Agreement with DuChemBioH.....II-108
1$100
   H. Lundbeck A/S Inks Agreement with IBC.....II-109
Xenon Takes Over XEN1101.....II-109
Bristol-Myers Squibb Inks Two Separate Agreement with Biogen & Roche.....II-109
Valeo Pharma Partners with Zambon.....II-109
Sumitomo Dainippon Pharma Inks License Agreement with Bukwang.....II-109
Eisai Inks Agreement with Meiji Seika Pharma.....II-109
Actavis UK & Ireland Taken Over by Accord Healthcare.....II-109
Piramal Takes Over Mallinckrodt.....II-109
1$100
   Ataxion Takes Over Luc Therapeutics.....II-110
Otsuka to Take Over Neurovance.....II-110
nLife Partners with wave life sciences.....II-110
EISAI Inks Marketing and Distribution Agreement with Orion.....II-110
Sumitomo Dainippon Pharma Takes Over Tolero.....II-110
Zydus Cadila Takes Over Sentynl.....II-110
Takeda Partners with Ovid.....II-110
Lilly toTake Over CoLucid.....II-110
Aurobindo Pharma Takes Over Generis.....II-110
1$100
   Genkyotex Merges with Genticel.....II-111
Eisai Inks Agreement with Keio University.....II-111
Evotec Partners with Celgene.....II-111
AstraZeneca Inks Agreement with Lilly.....II-111
Takeda and Lightstone Introduces Cerevance.....II-111
Pacira Partners with GeneAlign.....II-111
Allergan Takes Over Chase Pharmaceuticals.....II-111
Synapcell Partners with University of Utah.....II-111
1$100
   BlackThorn Therapeutics to Develop Novel.....II-112
Evotec Partners with UCB.....II-112
Ligand Enters License Agreement with Seelos Therapeutics.....II-112
Takeda Partners with Affilogic.....II-112
Riemser Takes Over CNS Portfolio from Dolorgiet.....II-112
OPKO Takes Over Transition Therapeutics, Inc.....II-112
Sunovion to Take Over Cynapsus Therapeutics.....II-112
Boehringer Ingelheim Partners with Saniona.....II-112
1$100
   Denali Partners with F-star Modular Antibody Technology.....II-113
Scintilla Takes Over Semnur Pharmaceuticals.....II-113
Pfizer Takes Over Bamboo Therapeutics.....II-113
Pfizer Partners with IBM.....II-113
Lupin Acquires 21 Branded Drugs from Shionogi.....II-113
Teva Takes Over Actavis Generics.....II-113
Chronos Takes Over Pre-clinical Programmes from Shire.....II-113
Otsuka & IBM Inks Agreement to Establish Otsuka Digital Health.....II-113
1$100
   Aspen Inks Agreement with AstraZeneca AB and AstraZeneca UK.....II-114
Merck Acquires Afferent Pharmaceuticals.....II-114
Centrexion Takes Over three Analgesic Candidates from Boehringer Ingelheim.....II-114
Reset Partners with Alkermes.....II-114
Zambon & Newron Pharmaceuticals Expands its Market.....II-114
Eisai Inks Agreement with Esteve.....II-114
Upsher-Smith Partners with Saniona.....II-114
1$100
   Acorda Agrees to Take Over Biotie Therapies.....II-115
Eisai Inks Agreement with Sysmex.....II-115
UCB Inks Agreement with Baylor College.....II-115
GTCR Partners with Ed Fiorentino.....II-115
Boehringer Ingelheim Inks Agreement with Arena.....II-115
PsychoGenics Partners with ADDF.....II-115
Takeda Inks Agreement with NsGene.....II-115
1$100
   AbbVie Inc. (USA).....II-116
Alkermes Plc. (Ireland).....II-116
1$100
   Allergan, Plc (Ireland).....II-1171$100
   Amneal Pharmaceuticals, LLC (USA).....II-118
AstraZeneca Plc (UK).....II-118
1$100
   BIAL Group (Portugal).....II-119
Bristol-Myers Squibb (USA).....II-119
1$100
   Eisai Co., Ltd. (Japan).....II-1201$100
   Endo Pharmaceuticals Inc. (USA).....II-121
Eli Lilly and Co. (USA).....II-121
1$100
   F. Hoffmann-La Roche Ltd. (Switzerland).....II-122
Fabre-Kramer Pharmaceuticals, Inc. (USA).....II-122
GlaxoSmithKline (UK).....II-122
1$100
   H. Lundbeck A/S (Denmark).....II-1231$100
   Johnson & Johnson (USA).....II-1241$100
   Janssen Pharmaceuticals, Inc. (USA).....II-125
Merck & Co., Inc. (USA).....II-125
1$100
   Neurocrine Biosciences, Inc. (USA).....II-126
Novartis AG (Switzerland).....II-126
1$100
   Otsuka Pharmaceutical Co., Ltd. (Japan).....II-127
Pfizer, Inc. (USA).....II-127
2$200
   Purdue Pharma L.P. (USA).....II-129
Sanofi S.A (France).....II-129
1$100
   Shire Plc (UK).....II-1301$100
   Strides Shasun Limited (India).....II-131
Sumitomo Dainippon Pharma Co., Ltd. (Japan).....II-131
1$100
   Sunovion Pharmaceuticals, Inc. (USA).....II-132
Takeda Pharmaceutical Co., Ltd. (Japan).....II-132
1$100
   Teva Pharmaceutical Industries Ltd. (Israel).....II-133
UCB Group (Belgium).....II-133
1$100
   Table 13: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1341$350
   Table 14: World Historic Review for CNS Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1351$350
   Table 15: World 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1361$350
   Table 16: World Recent Past, Current & Future Analysis for Anti-Alzheimer’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1371$350
   Table 17: World Historic Review for Anti-Alzheimer’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1381$350
   Table 18: World 14-Year Perspective for Anti-Alzheimer’s by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1391$350
   Table 19: World Recent Past, Current & Future Analysis for Anti-Parkinson’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1401$350
   Table 20: World Historic Review for Anti-Parkinson’s by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1411$350
   Table 21: World 14-Year Perspective for Anti-Parkinson’s by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1421$350
   Table 22: World Recent Past, Current & Future Analysis for Anti-Epilepsy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1431$350
   Table 23: World Historic Review for Anti-Epilepsy by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1441$350
   Table 24: World 14-Year Perspective for Anti-Epilepsy by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1451$350
   Table 25: World Recent Past, Current & Future Analysis for Pain Management by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1461$350
   Table 26: World Historic Review for Pain Management by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1471$350
   Table 27: World 14-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1481$350
   Table 28: World Recent Past, Current & Future Analysis for Anti-Psychotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1491$350
   Table 29: World Historic Review for Anti-Psychotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1501$350
   Table 30: World 14-Year Perspective for Anti-Psychotics by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1511$350
   Table 31: World Recent Past, Current & Future Analysis for Anti-Depressants by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1521$350
   Table 32: World Historic Review for Anti-Depressants by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1531$350
   Table 33: World 14-Year Perspective for Anti-Depressants by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1541$350
   Table 34: World Recent Past, Current & Future Analysis for Others by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1551$350
   Table 35: World Historic Review for Others by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1561$350
   Table 36: World 14-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1571$350
   A. Market Analysis.....III-1
The Largest CNS Therapeutics Market Globally.....III-1
Patent Expiries of Leading CNS Drugs in the US.....III-1
1$75
   Aging Population: A Strong Demographic Driver.....III-2 1$75
   Table 37: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart).....III-3

Table 38: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart).....III-3
1$200
   Focus on Select Markets.....III-4
Alzheimer’s Market.....III-4
Anti-depressant Drugs.....III-4
Usage of Antidepressants Surges in the US.....III-4
1$75
   Anti-Epilepsy Market.....III-5
Epilepsy – A Major Concern for the Healthcare Industry.....III-5
A Glance at Epilepsy Statistics.....III-5
1$75
   Anti-Epilepsy Drugs.....III-6
The US Epilepsy Market: Patent Expiry of Select Major Drugs.....III-6
Epilepsy in Children.....III-6
1$75
   Growing Competition from Generics.....III-7
Pain Management Market.....III-7
Consumers in the US Seek Different Options for Chronic Pain Management.....III-7
1$75
   Neuropathic Pain Market.....III-8
Anti-Psychotic Drugs Market.....III-8
Mental Illnesses – Epidemiology.....III-8
1$75
   Facts & Figures.....III-9
Table 39: Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group (includes corresponding Graph/Chart).....III-9
Popular Antipsychotic Drugs in the US.....III-9
1$200
   Anti-Psychotic Drugs by FDA Approved Age and Indication in the US.....III-10
Table 40: The US Anti-Psychotic Drugs Market (2016): Percentage Share Breakdown of Value Sales by Indication (includes corresponding Graph/Chart).....III-10
Surging Off-label Prescriptions.....III-10
1$200
   Generics Occupy Front Seat.....III-11
Rising Antipsychotic Use among Children – A Cause of Concern.....III-11
1$75
   ADHD Market.....III-12
Select Available ADHD Drugs in the US.....III-12
Table 41: The US ADHD Drugs Market by Drug Category (2016): Percentage Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants (includes corresponding Graph/Chart).....III-12
1$200
   Table 42: The US ADHD Drugs Market by Type (2016): Percentage Share Breakdown of Total Prescription Sales for Branded & Generic Drug Groups (includes corresponding Graph/Chart).....III-13
Adult ADHD Drugs Continue to Widen their Share.....III-13
Table 43: The US ADHD Drugs Market by Drug Category (2016): Percentage Share Breakdown of Total Prescriptions for Adult & Pediatric Patient Groups (includes corresponding Graph/Chart).....III-13
Product Launches.....III-13
3$200
   Strategic Corporate Developments.....III-162$150
   Select Key Players.....III-187$525
   B. Market Analytics.....III-25
Table 44: The US Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-25
1$200
   Table 45: The US Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-261$200
   Table 46: The US 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-271$200
   A. Market Analysis.....III-28
CNS Diseases: Facts & Figures.....III-28
Strategic Corporate Developments.....III-28
1$75
   B. Market Analytics.....III-29
Table 47: Canadian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-29
1$200
   Table 48: Canadian Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-301$200
   Table 49: Canadian 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-311$200
   A. Market Analysis.....III-32
Product Launches.....III-32
1$75
   Strategic Corporate Developments.....III-331$75
   Select Key Players.....III-343$225
   B. Market Analytics.....III-37
Table 50: Japanese Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-37
1$200
   Table 51: Japanese Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-381$200
   Table 52: Japanese 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-391$200
   A. Market Analysis.....III-40
Ageing Population Boosts Demand.....III-40
1$75
   Table 53: European Country-wise Statistics of 65+ Population as % of Total Population: As on January 1, 2015 (includes corresponding Graph/Chart).....III-411$200
   European Patent Expiries of Select CNS Drugs.....III-42
Pain Management Market.....III-42
Neuropathic Pain Market Witnesses Foray of Generics.....III-42
1$75
   Anti-Psychotics Market.....III-43
Demand for Antipsychotics for Bipolar Disorder Upbeat.....III-43
1$75
   Strategic Corporate Development.....III-441$75
   B. Market Analytics.....III-45
Table 54: European Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-45
1$200
   Table 55: European Historic Review for CNS Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-461$200
   Table 56: European Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-471$200
   Table 57: European Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-481$200
   Table 58: European 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-491$200
   Table 59: European 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-501$200
   A. Market Analysis.....III-51
Product Launch.....III-51
Strategic Corporate Developments.....III-51
Sanofi – A Key French Player.....III-51
2$150
   B. Market Analytics.....III-53
Table 60: French Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-53
1$200
   Table 61: French Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-541$200
   Table 62: French 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-551$200
   A. Market Analysis.....III-56
Strategic Corporate Developments.....III-56
1$75
   B. Market Analytics.....III-57
Table 63: German Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-57
1$200
   Table 64: German Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-581$200
   Table 65: German 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-591$200
   A. Market Analysis.....III-60
Market Snapshots.....III-60
1$75
   B. Market Analytics.....III-61
Table 66: Italian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-61
1$200
   Table 67: Italian Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-621$200
   Table 68: Italian 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-631$200
   A. Market Analysis.....III-64
NICE Recommendations On CNS Therapeutics.....III-64
Product Launches.....III-64
1$75
   Strategic Corporate Developments.....III-651$75
   Select Key Players.....III-663$225
   B. Market Analytics.....III-69
Table 69: The UK Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-69
1$200
   Table 70: The UK Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-701$200
   Table 71: The UK 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-711$200
   A. Market Analysis.....III-72
Product Launches.....III-72
Strategic Corporate Development.....III-72
1$75
   B. Market Analytics.....III-73
Table 72: Spanish Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-73
1$200
   Table 73: Spanish Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-741$200
   Table 74: Spanish 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-751$200
   Market Analysis.....III-76
Table 75: Russian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-76
1$200
   Table 76: Russian Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-771$200
   Table 77: Russian 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-781$200
   A. Market Analysis.....III-79
Product Launches.....III-79
1$75
   Strategic Corporate Developments.....III-802$150
   Select Key Players.....III-825$375
   B. Market Analytics.....III-87
Table 78: Rest of Europe Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-87
1$200
   Table 79: Rest of Europe Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-881$200
   Table 80: Rest of Europe 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-891$200
   A. Market Analysis.....III-90
India & China Offer Significant Growth Opportunities.....III-90
1$75
   Table 81: China and India Lead Global Population (2015): Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Millions) by Age Group (includes corresponding Graph/Chart).....III-91
Growing Antipsychotics Market in Asia.....III-91
China: The Primary Market for CNS Drugs in Asia-Pacific.....III-91
1$200
   Select Anti-Schizophrenia Drugs Available in China.....III-921$75
   Other Available CNS Drugs in China.....III-93
Product Launches.....III-93
Strategic Corporate Developments.....III-93
1$75
   Strides Shasun Limited – A Key Indian Player.....III-941$75
   B. Market Analytics.....III-95
Table 82: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-95
1$200
   Table 83: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-961$200
   Table 84: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-971$200
   Table 85: Asia-Pacific Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-981$200
   Table 86: Asia-Pacific 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for China, India and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-991$200
   Table 87: Asia-Pacific 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-1001$200
   Market Analysis.....III-101
Table 88: Latin American Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-101
1$200
   Table 89: Latin American Historic Review for CNS Therapeutics by Geographic Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-1021$200
   Table 90: Latin American Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-1031$200
   Table 91: Latin American Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-1041$200
   Table 92: Latin American 14-Year Perspective for CNS Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin America Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-1051$200
   Table 93: Latin American 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-1061$200
   A. Market Analysis.....III-107
Teva Pharmaceutical Industries Ltd. – A Key Israeli Company.....III-107
1$75
   B. Market Analytics.....III-108
Table 94: Rest of World Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-108
1$200
   Table 95: Rest of World Historic Review for CNS Therapeutics by Product Segment - Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-1091$200
   Table 96: Rest of World 14-Year Perspective for CNS Therapeutics by Product Segment - Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-1101$200
  
Total Companies Profiled: 162 (including Divisions/Subsidiaries - 183)

Region/Country Players

The United States 79 Canada 13 Japan 15 Europe 50 France 5 Germany 9 The United Kingdom 9 Italy 2 Spain 3 Rest of Europe 22 Asia-Pacific (Excluding Japan) 19 Middle East 4 Latin America 1 Africa 2
Click here to request a full table of contents and more details on this project.